Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
17.50
0.00 (0.00%)
May 22, 2026, 4:00 PM EDT - Market closed
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $6.25M in the quarter ending February 28, 2026, a decrease of -66.12%. This brings the company's revenue in the last twelve months to $71.78M, up 27.23% year-over-year. In the fiscal year ending November 30, 2025, Nurix Therapeutics had annual revenue of $83.98M with 53.95% growth.
Revenue (ttm)
$71.78M
Revenue Growth
+27.23%
P/S Ratio
25.21
Revenue / Employee
$226,432
Employees
317
Market Cap
1.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2025 | 83.98M | 29.43M | 53.95% |
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | 31.12M | -6.33M | -16.91% |
| Nov 30, 2018 | 37.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| Lakefront Biotherapeutics NV | 1.20B |
| Vericel | 292.09M |
| Iovance Biotherapeutics | 285.61M |
| Syndax Pharmaceuticals | 217.17M |
| Intellia Therapeutics | 66.09M |
| Ocular Therapeutix | 52.04M |
| Stoke Therapeutics | 32.08M |
NRIX News
- 5 days ago - Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 11 days ago - Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting - GlobeNewsWire
- 12 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 13 days ago - Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 6 weeks ago - Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo - TheFly
- 6 weeks ago - Nurix Therapeutics price target lowered to $34 from $35 at Stifel - TheFly